MXPA03006746A - Composicion farmaceutica que comprende una dispersion solida de un polimero de ftalato de hidroxipropilmetilcelulosa. - Google Patents

Composicion farmaceutica que comprende una dispersion solida de un polimero de ftalato de hidroxipropilmetilcelulosa.

Info

Publication number
MXPA03006746A
MXPA03006746A MXPA03006746A MXPA03006746A MXPA03006746A MX PA03006746 A MXPA03006746 A MX PA03006746A MX PA03006746 A MXPA03006746 A MX PA03006746A MX PA03006746 A MXPA03006746 A MX PA03006746A MX PA03006746 A MXPA03006746 A MX PA03006746A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
solid dispersion
hydroxypropylmethylcellulose phthalate
phthalate polymer
polymer
Prior art date
Application number
MXPA03006746A
Other languages
English (en)
Spanish (es)
Inventor
Nicola Bateman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03006746A publication Critical patent/MXPA03006746A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA03006746A 2001-02-27 2002-02-25 Composicion farmaceutica que comprende una dispersion solida de un polimero de ftalato de hidroxipropilmetilcelulosa. MXPA03006746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
PCT/SE2002/000327 WO2002067904A1 (en) 2001-02-27 2002-02-25 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Publications (1)

Publication Number Publication Date
MXPA03006746A true MXPA03006746A (es) 2003-10-24

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006746A MXPA03006746A (es) 2001-02-27 2002-02-25 Composicion farmaceutica que comprende una dispersion solida de un polimero de ftalato de hidroxipropilmetilcelulosa.

Country Status (14)

Country Link
US (1) US20040138231A1 (cg-RX-API-DMAC7.html)
EP (1) EP1365746A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004527489A (cg-RX-API-DMAC7.html)
KR (1) KR20040011469A (cg-RX-API-DMAC7.html)
CN (1) CN1533268A (cg-RX-API-DMAC7.html)
BR (1) BR0206960A (cg-RX-API-DMAC7.html)
CA (1) CA2435815A1 (cg-RX-API-DMAC7.html)
GB (1) GB0104752D0 (cg-RX-API-DMAC7.html)
IL (1) IL156830A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006746A (cg-RX-API-DMAC7.html)
NO (1) NO20033782D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ527080A (cg-RX-API-DMAC7.html)
WO (1) WO2002067904A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305386B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2720851A1 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
LT2346495T (lt) * 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
KR20240124428A (ko) 2016-09-30 2024-08-16 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (cg-RX-API-DMAC7.html) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US6312726B1 (en) * 1993-08-20 2001-11-06 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
IL139406A (en) * 1998-05-02 2004-07-25 Astrazeneca Ab Heterocyclic derivatives inhibiting factor XA, pharmaceutical preparations containing them and their use as a drug in the treatment of diseases or conditions mediated by factor XA in warm-blooded animals
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs

Also Published As

Publication number Publication date
NZ527080A (en) 2005-02-25
WO2002067904A1 (en) 2002-09-06
ZA200305386B (en) 2004-10-11
BR0206960A (pt) 2004-03-09
CA2435815A1 (en) 2002-09-06
NO20033782L (no) 2003-08-26
KR20040011469A (ko) 2004-02-05
US20040138231A1 (en) 2004-07-15
IL156830A0 (en) 2004-02-08
NO20033782D0 (no) 2003-08-26
JP2004527489A (ja) 2004-09-09
GB0104752D0 (en) 2001-04-18
CN1533268A (zh) 2004-09-29
EP1365746A1 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
MXPA03010007A (es) USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
MXPA03007215A (es) Formulaciones farmaceuticas.
MXPA03006884A (es) Formulacion farmaceutica.
MXPA03007641A (es) Formulacion farmaceutica.
GB0111597D0 (en) Pharmaceutical compositions
AU2002341205A1 (en) Pharmaceutical compositions comprising cyclosporin
AU2002337803A1 (en) Sustained release pharmaceutical compositions
AUPR602501A0 (en) Sustained release pharmaceutical composition
AU2002302147A1 (en) Pharmaceutical composition
MXPA03006746A (es) Composicion farmaceutica que comprende una dispersion solida de un polimero de ftalato de hidroxipropilmetilcelulosa.
AU2002351739A1 (en) Solid dose micro implant
GB0129872D0 (en) Novel pharmaceutical
ZA200110500B (en) Pharmaceutical composition.
GB2382302B (en) Pharmaceutical compositions
MXPA03007318A (es) Composicion farmaceutica.
AU2002361450A1 (en) Novel pharmaceutical
GB0130509D0 (en) Novel pharmaceutical
GB0130511D0 (en) Novel pharmaceutical
GB0129876D0 (en) Novel pharmaceutical
ZA200110499B (en) Pharmaceutical composition.
ZA200402731B (en) Pharmaceutical formulation.
GB0126732D0 (en) Pharmaceutical compositions
AU2002235803A1 (en) Pharmaceutical tablet comprising paroxetine mesylate
AU2002100921A4 (en) Pharmaceutical composition
ZA200110502B (en) Pharmaceutical composition.